LY4256984 / Eli Lilly - LARVOL DELTA

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Amyotrophic Lateral Sclerosis • CNS Disorders

Design of the multiple ascending dose (MAD) trial of UNC13A splice modulating ASO LY4256984 in patients with sporadic amyotrophic lateral sclerosis (ALS) (ALS-MND 2025) - "Results to date: The trial initiated enrollment in 2025 and plans to be conducted in ≥10 sites. We will test the safety and tolerability of intrathecally administered UNC13A splice modulating ASO LY4256984 in patients with sporadic ALS."

Clinical • Amyotrophic Lateral Sclerosis • CNS Disorders • TARDBP

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders